Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $61.65 +3.56%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.20), $0.09 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $21.74 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Socket Mobile (SCKT) Reports Q3 Loss of $0.09
- Solid Biosciences (SLDB) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
